DK3601296T3 - 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere - Google Patents
2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere Download PDFInfo
- Publication number
- DK3601296T3 DK3601296T3 DK18716193.0T DK18716193T DK3601296T3 DK 3601296 T3 DK3601296 T3 DK 3601296T3 DK 18716193 T DK18716193 T DK 18716193T DK 3601296 T3 DK3601296 T3 DK 3601296T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxo
- inhibitors
- cancer
- compounds
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D497/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163781 | 2017-03-30 | ||
| US201762565281P | 2017-09-29 | 2017-09-29 | |
| EP17194084 | 2017-09-29 | ||
| ARP180100778A AR111200A1 (es) | 2017-03-30 | 2018-03-28 | Derivados de tiocarbamato como inhibidores de a2a y métodos para usar en el tratamiento de cánceres |
| PCT/EP2018/058301 WO2018178338A1 (en) | 2017-03-30 | 2018-03-30 | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3601296T3 true DK3601296T3 (da) | 2022-08-29 |
Family
ID=61911575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18716193.0T DK3601296T3 (da) | 2017-03-30 | 2018-03-30 | 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10995101B2 (da) |
| EP (2) | EP4112623A1 (da) |
| JP (2) | JP7197558B2 (da) |
| KR (2) | KR102640927B1 (da) |
| CN (3) | CN115991679A (da) |
| AU (1) | AU2018246355B2 (da) |
| BR (1) | BR112019020421A8 (da) |
| CA (1) | CA3058260A1 (da) |
| DK (1) | DK3601296T3 (da) |
| ES (1) | ES2926158T3 (da) |
| HR (1) | HRP20221039T1 (da) |
| HU (1) | HUE059990T2 (da) |
| IL (2) | IL300149A (da) |
| LT (1) | LT3601296T (da) |
| MX (2) | MX2019011743A (da) |
| PL (1) | PL3601296T3 (da) |
| RS (1) | RS63557B1 (da) |
| SI (1) | SI3601296T1 (da) |
| TW (1) | TWI836960B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111163780A (zh) | 2017-07-18 | 2020-05-15 | 诺维逊生物股份有限公司 | 作为腺苷拮抗剂的杂环化合物 |
| CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| CN113226324B (zh) * | 2018-09-11 | 2024-12-31 | Iteos比利时公司 | 作为a2a抑制剂的硫代氨基甲酸酯衍生物、其药物组合物以及与抗癌剂的组合 |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
| EP3911324A4 (en) | 2019-01-18 | 2022-08-17 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
| JP2022517419A (ja) | 2019-01-18 | 2022-03-08 | ニューベイション・バイオ・インコーポレイテッド | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| CN114539265B (zh) * | 2022-03-02 | 2023-07-21 | 中山大学 | 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6921825B2 (en) | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
| US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| TWI288137B (en) * | 2000-05-26 | 2007-10-11 | Schering Corp | Adenosine A2a receptor antagonists |
| EP1618108A2 (en) * | 2003-04-09 | 2006-01-25 | Biogen Idec MA Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists |
| PE20060185A1 (es) | 2004-04-21 | 2006-03-20 | Schering Corp | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA |
| WO2007140181A2 (en) | 2006-05-26 | 2007-12-06 | King Pharmaceuticals Research And Development, Inc. | Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist |
| US7691869B2 (en) | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
| CA2694987A1 (en) | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Combinations for the treatment of b-cell proliferative disorders |
| US20110237599A1 (en) | 2010-03-10 | 2011-09-29 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| JP5843869B2 (ja) | 2010-09-24 | 2016-01-13 | アドヴィナス・セラピューティックス・リミテッド | アデノシン受容体拮抗薬としての縮合三環化合物 |
| WO2012055015A1 (en) | 2010-10-26 | 2012-05-03 | Alberta Health Services | Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer |
| WO2012135084A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| KR102611446B1 (ko) | 2017-01-20 | 2023-12-06 | 아르커스 바이오사이언시즈 인코포레이티드 | 암-관련 장애의 치료를 위한 아졸로피리미딘 |
| WO2018178338A1 (en) | 2017-03-30 | 2018-10-04 | Iteos Therapeutics | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
| JP7391022B2 (ja) | 2017-12-19 | 2023-12-04 | インペティス・バイオサイエンシーズ・リミテッド | がんの処置のための医薬組成物 |
| CN113226324B (zh) | 2018-09-11 | 2024-12-31 | Iteos比利时公司 | 作为a2a抑制剂的硫代氨基甲酸酯衍生物、其药物组合物以及与抗癌剂的组合 |
| US11376255B2 (en) * | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
| JP7641894B2 (ja) | 2018-09-27 | 2025-03-07 | アイテオ ベルギウム エスエー | がん治療におけるｅｎｔファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ |
-
2018
- 2018-03-30 EP EP22165965.9A patent/EP4112623A1/en active Pending
- 2018-03-30 LT LTEPPCT/EP2018/058301T patent/LT3601296T/lt unknown
- 2018-03-30 BR BR112019020421A patent/BR112019020421A8/pt active Search and Examination
- 2018-03-30 JP JP2020503355A patent/JP7197558B2/ja active Active
- 2018-03-30 CN CN202211658370.5A patent/CN115991679A/zh active Pending
- 2018-03-30 IL IL300149A patent/IL300149A/en unknown
- 2018-03-30 CN CN202211706953.0A patent/CN115873022A/zh active Pending
- 2018-03-30 PL PL18716193.0T patent/PL3601296T3/pl unknown
- 2018-03-30 HR HRP20221039TT patent/HRP20221039T1/hr unknown
- 2018-03-30 CN CN201880034926.9A patent/CN110678472B/zh active Active
- 2018-03-30 KR KR1020197031322A patent/KR102640927B1/ko active Active
- 2018-03-30 ES ES18716193T patent/ES2926158T3/es active Active
- 2018-03-30 HU HUE18716193A patent/HUE059990T2/hu unknown
- 2018-03-30 EP EP18716193.0A patent/EP3601296B1/en active Active
- 2018-03-30 AU AU2018246355A patent/AU2018246355B2/en active Active
- 2018-03-30 CA CA3058260A patent/CA3058260A1/en active Pending
- 2018-03-30 DK DK18716193.0T patent/DK3601296T3/da active
- 2018-03-30 MX MX2019011743A patent/MX2019011743A/es unknown
- 2018-03-30 RS RS20220794A patent/RS63557B1/sr unknown
- 2018-03-30 SI SI201830747T patent/SI3601296T1/sl unknown
- 2018-03-30 KR KR1020247005971A patent/KR20240027885A/ko active Pending
- 2018-03-30 TW TW112113401A patent/TWI836960B/zh active
-
2019
- 2019-03-14 US US16/354,022 patent/US10995101B2/en active Active
- 2019-09-26 IL IL269710A patent/IL269710B2/en unknown
- 2019-09-30 MX MX2022005298A patent/MX2022005298A/es unknown
-
2020
- 2020-08-14 US US16/993,897 patent/US20210198281A1/en not_active Abandoned
-
2022
- 2022-09-21 US US17/949,595 patent/US20230159564A1/en active Pending
- 2022-12-15 JP JP2022199962A patent/JP2023027282A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3601296T3 (da) | 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere | |
| DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
| DK3285809T3 (da) | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
| DK3149001T3 (da) | Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere | |
| DK3277681T3 (da) | Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer | |
| LT3902803T (lt) | Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui | |
| IL261015A (en) | History of methylamine as lysis oxidase inhibitors for cancer treatment | |
| DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3860990T3 (da) | Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer | |
| DK3766885T3 (da) | Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer | |
| DK3532067T3 (da) | Liposomal formulering til anvendelse til behandling af cancer | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| HUE053927T2 (hu) | Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
| DK3478284T3 (da) | Forbindelser og sammensætninger til behandling af cancer | |
| IL274198A (en) | Use of Nox inhibitors to treat cancer | |
| DK3471722T3 (da) | Forbindelser, sammensætninger og fremgangsmåder til forebyggelse og/eller behandling af cancer | |
| DK3383872T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling |